William Kaelin is the Nobel laureate whose work on VHL and HIF-2α led directly to belzutifan.
William G. Kaelin Jr. is the Sidney Farber Professor of Medicine and an HHMI Investigator at Dana-Farber Brigham Cancer Center. He is the Nobel laureate who shared the 2019 Nobel Prize in Physiology or Medicine for discovering how cells sense oxygen, through work on the VHL tumour suppressor and hypoxia-inducible factor. His selected paper shows that HIF alpha is targeted for VHL-mediated destruction by proline hydroxylation. His VHL and HIF work defined the target for HIF-2 alpha inhibitors such as belzutifan, now approved in kidney cancer.
| Title | Journal | Year |
|---|---|---|
| HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Science | 2001 |
Shares VHL / HIF oxygen sensing, HIF-2α, Belzutifan, Renal cell carcinoma.
Shares HIF-2α, Belzutifan, Renal cell carcinoma.
Shares VHL / HIF oxygen sensing, HIF-2α, Belzutifan, Renal cell carcinoma.
Shares HIF-2α, Belzutifan, Dana-Farber Brigham Cancer Center, Renal cell carcinoma.
Shares HIF-2α, Belzutifan, Renal cell carcinoma.
Shares Belzutifan, Renal cell carcinoma.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares Belzutifan, Renal cell carcinoma.